(UroToday.com) A series of talks were given on the regulations surrounding clinical and genomic data sharing in an attempt to establish a tissue biobank shepherded by the IBCN.
Dr. Lerner was tasked with providing some lessons learned from a very successful TCGA effort. The Cancer Genome Atlas (TCGA) project was a joint effort between the National Cancer Institute and National Human Genome Research Institute that characterized over 20,000 primary cancer and matched normal samples in 33 cancer types. The project generated 2.5 pentabyte (1,000 terabytes or 1,000,000 gigabytes) of genomic, epigenomic, transcriptomic, and proteomic data. The first manuscript in bladder cancer was published in 2014 1, including data gathered from 131 tumors, detailing 32 SMGs, 9 of which were novel at the time to bladder cancer. Pathway alterations in characterized in cell-cycle regulation (93%), chromatin regulation (89%) and others. Four expert genitourinary pathologist reviewed all 412 tumors eventually profiled in a publication in 2017.2 There were no low grade tumors, 3 squamous cell cancers, one patient with T1HG, and 13% with variant histology with variants consisting of <50% of the entire tumor. Of these, 4 were squamous, 4 small cell neuroendocrine, 4 plasmacytoid, and 2 micropapillary.
Dr. Lerner also highlighted the Cancer Imaging Archive which houses full set of cross-sectional imaging obtained from 120 patient included within TCGA. Efforts have already begun on deep dives to correlate imaging findings with genomic data. Dr. Lerner ended with a reminder that per the NIH Data Management and Sharing Policy – effective 1/25/2023 – prospective planning and follow through will be expected, with wide spread implications for legal, ethical, technical issues that may limit the extent of data sharing, in an attempt to address the issue that all scientific data needs to validate and replicable.
Presented by: Seth Paul Lerner, MD, FACS, Professor of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Scott Department of Urology, Baylor College of Medicine
Written by: Roger Li, Urologic Oncologist, Moffitt Cancer Center, during the International Bladder Cancer Network Annual Meeting, September 28-October 1, 2022, Barcelona, Spain
References:
- Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-322.
- Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171(3):540-556.e525.